Regulatory News
Wednesday, December 14, 2016
BRIEF-Concert Pharmaceuticals announces CTP-543 positive top-line phase 1 results
* Concert pharmaceuticals - phase 2A trial expected to
commence in Q1 next year and topline primary outcome data
expected by end of 2017
Read more
No comments:
Post a Comment
Newer Post
Older Post
Home
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment